Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Generative AI in pharmaceutical R&D: From large language models to AI agents to regulation
0
Zitationen
2
Autoren
2026
Jahr
Abstract
Generative AI (GenAI) is reshaping pharmaceutical R&D, offering transformative potential across research and development. Applications of GenAI include scientific insight generation, mining large biological datasets to study diseases, molecule design, clinical document drafting, and many others. The DISRUPT-DS roundtable, a forum that brings together data science leaders from major pharmaceutical companies, has recently conducted an analysis of GenAI in R&D. Here, the roundtable participants report key findings from this effort. Specifically, we discuss areas that are regulatory-relevant, including GenAI-powered document drafting and statistical programming, and we explore emerging topics, such as AI agents and foundation models. The goal of this work is to provide an industry-wide perspective of where GenAI is today and how it might evolve in the future.
Ähnliche Arbeiten
Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI
2019 · 8.245 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.102 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 7.468 Zit.
Proceedings of the 19th International Joint Conference on Artificial Intelligence
2005 · 5.776 Zit.
Peeking Inside the Black-Box: A Survey on Explainable Artificial Intelligence (XAI)
2018 · 5.429 Zit.